Financial Data and Key Metrics Changes - The company reported record third-quarter revenue of $39 million, representing a 21% year-over-year increase [13] - Adjusted EBITDA grew 3% year-over-year to $13 million, with an adjusted EBITDA margin of 33% compared to 39% in the previous year [16] - Gross profits increased 17% to $35.6 million, while the gross profit margin decreased to 91.2% from 94.7% year-over-year [13][14] - Free cash flow was $9.6 million, down from $14.2 million in the previous year due to timing differences [16][17] - The company revised its full-year guidance to approximately $165 million in revenue and $58 million in adjusted EBITDA, reflecting continued headwinds from poor search dynamics [18][19] Business Line Data and Key Metrics Changes - Sports data services revenue quadrupled to $9.2 million, accounting for 25% of total revenue [5][13] - The marketing business revenue remained flat year-over-year, with new depositing customers (NDCs) down 13% to 101,000 [13] - Subscription revenue constituted 24% of total revenue, and recurring revenue was 49% of total third-quarter revenue [13] Market Data and Key Metrics Changes - The North American market saw a 55% year-over-year growth in the third quarter, primarily driven by sports data services [45] - The marketing business in the U.S. grew year-over-year, while it was flat globally, with a decline in Canada impacting overall performance [45] Company Strategy and Development Direction - The company is focusing on the growth of its sports data services business, which is expected to continue growing organically at a healthy pace in 2026 and beyond [6][12] - The marketing business is expected to grow in 2026 and beyond, with a focus on diversifying away from SEO channels [20][41] - The company aims to leverage its strong cash flow to invest in product development and diversification strategies [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of search rankings and the potential for revenue improvement as Google addresses quality issues in search results [26][28] - The company anticipates mid-teens revenue growth and around 10% adjusted EBITDA growth as it heads into 2026 [39] - Management acknowledged the challenges faced in the marketing business but emphasized the resilience and potential for future growth [21][22] Other Important Information - The company acquired Spotlight.Vegas for $8 million and repurchased approximately 562,000 shares for a total of $4.7 million during the quarter [17] - The company has $70.5 million of undrawn capacity in its credit facility, providing flexibility for capital structure optimization [17][63] Q&A Session Summary Question: What gives confidence to grow the business in 2026 despite current challenges? - Management noted improvements in Google search rankings towards the end of October, leading to better traffic and revenue [26][27] Question: How is the B2C side of the business performing? - Consumer data services revenue grew marginally, with RotoWire subscriber numbers up 21% year-on-year [30] Question: What is the progress on OpticOdds commercialization? - Management indicated a clear product-market fit and a long runway for growth, with opportunities beyond data and bet settlement [35] Question: How does the company view the upcoming U.K. budget? - An increase in gaming duty could negatively impact player lifetime values, but management does not expect significant growth or decline in the U.K. market next year [61] Question: How is the company thinking about leverage and capital allocation? - Management is focused on optimizing capital allocation, with no plans to leverage beyond existing credit facilities until there is more growth visibility [63]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with a cash position of EUR 56.4 million, providing runway through the end of Q3 2026 to deliver on key milestones [26] Business Line Data and Key Metrics Changes - Lacutamab received FDA clearance to initiate the TELLOMAK III phase three trial in cutaneous T-cell lymphoma, with expectations for accelerated approval in Sézary syndrome based on robust phase two data [4][12] - IPH4502 is progressing well in its phase one trial, having reached a pharmacologically active dose and showing early signs of clinical activity [10][24] - Monalizumab is advancing in the PACIFIC-9 phase three trial, with top-line data expected in the second half of 2026 [11][24] Market Data and Key Metrics Changes - The annual incidence of Sézary syndrome is estimated at around 300 patients, with a prevalence of approximately 1,000 diagnosed patients in the U.S. [19] - For mycosis fungoides, approximately 3,000 new patients are diagnosed each year in the U.S., with one in four receiving systemic therapy [20] Company Strategy and Development Direction - The company is focusing investments on high-value clinical assets, including IPH4502, Lacutamab, and Monalizumab, while advancing next-generation ADC programs [6][24] - The development strategy for Lacutamab includes a stepwise approach starting with Sézary syndrome, followed by mycosis fungoides, and expanding to peripheral T-cell lymphoma [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory path for Lacutamab, indicating that the FDA has not requested additional substantial analyses beyond existing phase two data for accelerated approval [31] - There is growing momentum among KOLs for Lacutamab to become the preferred second-line option, with expectations that it may be used ahead of Mogamulizumab in mycosis fungoides [32][33] Other Important Information - The company is streamlining its organization to align with strategic objectives and ensure it remains fit for purpose [6] - The confirmatory phase three trial for Lacutamab is set to begin in the first half of 2026, with a potential BLA submission anticipated in early 2027 [12][31] Q&A Session Summary Question: What needs to be done for the potential Lacutamab commercial launch in Sézary syndrome? - The company aims to ensure Lacutamab is included in the NCCN guidelines prior to the BLA approval [27][28] Question: What can be expected from the upcoming data set for IPH4502? - The company hopes to present data from a cohort of patients in the Padcev resistance setting, with an interesting response rate and safety data [28][29] Question: Is the FDA looking for additional analyses for Lacutamab's accelerated approval? - The FDA has not indicated a need for further substantial analyses; the BLA approval will be based on existing TELLOMAK study data [31] Question: What are the expectations for the PACIFIC-9 study readout? - The company has good expectations based on previous studies, anticipating a positive outcome for the PACIFIC-9 study [40]

Financial Data and Key Metrics Changes - Cash-based operating expenses for Q2 2026 totaled $28.5 million, up from $18.2 million in the same period last year, indicating a significant increase in operational costs [17] - Net loss for Q2 2026 was $33.7 million, compared to a net loss of $41.9 million in the same period last year, showing an improvement in financial performance [17] - Cash flows used in operating activities were $34.5 million for Q2 2026, compared to $19.1 million in the same period last year, reflecting increased operational spending [17] - The company ended the quarter with cash, cash equivalents, and investments of $83.8 million [17] Business Line Data and Key Metrics Changes - CYB003, a proprietary deuterated psilocin analog, is in phase 3 studies for major depressive disorder, while CYB004, a deuterated dimethyltryptamine program, is in phase 2 for generalized anxiety disorder [5][8] - The phase 3 CYB003 program has received breakthrough therapy designation and has been granted additional clearances to commence a second phase 3 study in new geographies [5] - Enrollment for the phase 2 CYB004 study has been completed, with top-line data expected in the first calendar quarter of 2026 [9] Market Data and Key Metrics Changes - The phase 3 study for CYB003 targets approximately 330 participants across about 60 clinical sites globally, indicating a broad market reach [8] - The design of the studies aims to reflect real-world clinical populations, allowing for concomitant antidepressants or anxiolytics [9] Company Strategy and Development Direction - The company is focused on patient-centered care, rigorous science, and clear communication, with an emphasis on operational efficiency and scalability in clinical settings [3][4] - The capital plan is aligned with advancing programs towards major data readouts, following a recent financing of $175 million [4][14] - The strategy includes making therapies practical for clinics, with predictable session scheduling and minimal infrastructure requirements [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized a conservative regulatory posture and disciplined capital deployment to navigate upcoming data events [20] - The company is preparing for scale with a model built for clinical reality, aiming to deliver clean data on time [20] - The CEO search is active, and the company is focused on maintaining operational stability during the transition [19][20] Other Important Information - The company has strengthened its capital position through a registered direct offering, which provides flexibility to execute its plans [14] - The repayment of $20 million in convertible debt to High Trail was completed, with a 10% prepayment penalty [61] Q&A Session Summary Question: What would give confidence to move forward with CYB004 into phase 3? - Management is looking for directional data and trends in separation between the two arms of the study, with statistical significance being a bonus [24][25] Question: What is the minimum durability threshold needed to compete with Spravato for CYB003? - A minimum of 12 weeks of maintained effects is expected, with hopes for better durability based on phase 2 data showing effects lasting up to a year [30][31] Question: What is the operational status of the Approach trial and site activations? - Enrollment for CYB003 is on track to complete by mid-next year, with top-line data expected by the end of next year [34][35] Question: What engagement has occurred with payers regarding CYB003 and CYB004? - Preliminary market research has begun, but it is still early for detailed payer engagement [38] Question: What criteria were used for selecting clinical trial sites for the Approach trial? - A mix of experienced and less experienced sites were chosen, focusing on those with a proven track record in delivering high-quality data [44][45] Question: What is the status of the preclinical CYB005 program? - Preclinical profiling studies are ongoing, with no specific updates available yet [46] Question: How important is patient compliance with background antidepressant use in the pivotal trial for CYB003? - Patients are required to remain on their background antidepressant medication during the treatment period [69]

Financial Data and Key Metrics Changes - For the first nine months of 2025, total revenues were $43.6 million, a 24% increase compared to the same period last year [4] - Total revenues for the third quarter were $17.9 million, reflecting a decrease of 1% compared to the same period in 2024 [4] - The net loss for the nine-month period ended September 30, 2025, was $1.1 million, or $0.01 per share, compared to a net loss of $3.6 million, or $0.05 per share for the same period in 2024 [17] - For the three months ended September 30, 2025, net income was approximately $2.4 million, or $0.03 per share, compared to net income of $3.2 million, or $0.04 per share for the same period in 2024 [18] Business Line Data and Key Metrics Changes - Total revenues from selling goods for the nine months ended September 30, 2025, were $43.1 million, an increase of $8.3 million, or 24%, compared to $34.8 million for the same period in 2024 [10] - Revenues consisted of $18.6 million in sales of Elefabrio to Chiesi, $15.4 million in sales of Elelyso to Pfizer, and $9.1 million in sales of Elelyso to Fiocruz in Brazil [10] - For the three months ended September 30, 2025, total revenues from selling goods were $17.7 million, a decrease of $0.1 million, or 1%, compared to $17.8 million for the same period in 2024 [10] Market Data and Key Metrics Changes - The company recognizes revenues from sales to partners, and individual purchases vary from quarter to quarter as each partner controls its own inventories [11] - The company anticipates a significant increase in the overall gout market in the next five to six years, particularly for uncontrolled gout patients requiring uricases [22] Company Strategy and Development Direction - The operating strategy focuses on three pillars: driving commercial success with Elefabrio, advancing PRX-115 and other early-stage pipeline programs, and maintaining financial discipline [7] - The company is preparing for the phase two clinical trial of PRX-115, which is viewed as a strategic investment in the pipeline and long-term growth [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elefabrio's long-term potential and is working closely with Chiesi to support the re-examination of the once-in-four-weeks dosing regimen [6] - The company believes that the achievements in 2025 position it for long-term growth and value creation [19] Other Important Information - Research and development expenses for the nine months ended September 30, 2025, totaled $13.9 million, an increase of 58% compared to the prior year period [13] - Selling general and administrative expenses for the nine months ended September 30, 2025, were $8.2 million, down 11% from the same period last year [14] - The company had $29.4 million in cash and cash equivalents at September 30, 2025, sufficient to satisfy capital needs for at least 12 months [18] Q&A Session Summary Question: Timeline for the re-examination of the CHMP opinion on Elefabrio - The company expects to have an answer in Q1 of 2026 regarding the re-examination request [22] Question: Comments on the competitive landscape in treatment refractory gout - The company foresees a significant increase in the overall gout market and believes that if the phase two trial is successful, it could capture a substantial market share [22] Question: Predictability of royalty-based revenue recognition related to Elefabrio sales - The company continues to recognize what it sells to Chiesi's inventory and is optimistic about future revenue [23][24] Question: Cash runway guidance - The cash runway guidance is based on both operating expenditures and continued receipt of royalty-based revenue on Elefabrio [25][26] Question: Anticipated R&D growth during the phase two of PRX-115 - The company is taking into account the expenses associated with the phase two trial and has sufficient cash for more than 12 months to fund this trial [45]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company's cash, cash equivalents, and short-term investments were $55.3 million, an increase from $30 million as of June 30, 2025, and $44.1 million at the end of the previous year [14] - The net cash used in operating activities for the nine months ended September 30, 2025, was $21.3 million, compared to $15.6 million for the same period in 2024, primarily due to an increase in net loss [14][15] - The net losses for the three and nine month periods ending September 30, 2025, were $8.6 million and $24.0 million, respectively, higher than the $6.3 million and $16.5 million reported during the same periods in 2024 [17] Business Line Data and Key Metrics Changes - R&D expenses for the three and nine month periods ending September 30, 2025, were $6.4 million and $17.9 million, respectively, an increase from $5 million and $12.6 million in the same periods of the prior year, driven by the progress of the ReMEDy2 clinical trial and the expansion of the clinical team [16] - General and administrative expenses were $2.6 million and $7.3 million for the three and nine month periods ending September 30, 2025, up from $1.9 million and $5.7 million in 2024, attributed to increased non-cash share-based compensation and personnel costs [16][17] Market Data and Key Metrics Changes - The enrollment rates for the ReMEDy2 stroke trial have been lower than initially projected due to changes in stroke referral patterns, with current enrollment approaching 50% of the target for the interim futility analysis [10][11] - The company is currently utilizing actual enrollment rates from clinical trial sites instead of historical rates for more accurate forecasting [11][36] Company Strategy and Development Direction - The company is focusing on advancing its clinical programs, particularly DM199, which is positioned as a first-in-class treatment for preeclampsia and other vascular-related conditions [3][4] - Plans include expanding clinical studies into early onset preeclampsia and fetal growth restriction cohorts, with a U.S. phase two trial anticipated to begin soon [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current cash position to fund planned clinical studies and operations into the second half of 2027 [14] - The management team remains optimistic about the potential of DM199 based on encouraging interim results and the unique safety profile of the drug [4][22] Other Important Information - The company completed an in-person pre-IND meeting with the FDA, which was deemed productive, and is preparing for a phase two trial in the U.S. [9] - The Independent Data Safety Monitoring Board reported no safety concerns in the ReMEDy2 trial, allowing enrollment to continue without modification [12] Q&A Session Summary Question: Discussion on preeclampsia KOL community engagement and trial site considerations - Management highlighted extensive outreach to KOLs, receiving encouraging feedback regarding DM199's safety profile and efficacy in reducing blood pressure [20][22] Question: Details on protocol amendments and dosing outcomes - Management explained that part 1B will focus on IV dosing until delivery, allowing physicians to adjust dosing as needed based on patient response [23] Question: Clarification on the purpose of the 12 patient expansion cohort - The 12 patient cohort was intended to supplement the original plan for part 1B, focusing on the highest dose observed in cohort 10 [27][28] Question: Expectations for enrollment rates and site activation for the stroke trial - Management noted that historical enrollment rates were around 0.25, but current rates are slightly lower, with over 35 sites activated and more coming on board [35][36] Question: Meaningful change expectations for the modified Rankin Scale score at interim analysis - A 15% absolute improvement in the mRS score is expected to be meaningful, with adjustments made to the protocol to exclude severe stroke patients [42][43]

Financial Data and Key Metrics Changes - The company reported a net loss of $9 million or $0.19 per basic and diluted share for Q3 2025, compared to a net loss of $10.7 million or $0.29 per basic share in the prior year's quarter, indicating a decrease in net loss primarily due to lower operating expenses [15][16] - Research and development expenses were $4.6 million for Q3 2025, down from $6.8 million in the prior year, attributed to lower manufacturing and clinical expenses [16] - General and administrative expenses increased to $3.6 million in Q3 2025 from $3.4 million in the prior year, mainly due to higher professional fees [16] - Total operating expenses were $8.1 million for Q3 2025, down from $10.2 million in the prior year [17] - Cash balance as of September 30, 2025, was $26.2 million, down from $41.7 million at the beginning of the year [17] Business Line Data and Key Metrics Changes - The VERSATILE-002 trial showed a median overall survival of 39.3 months for patients with a combined positive score (CPS) of greater than or equal to one, with a progression-free survival (PFS) of 6.3 months among these patients [5][6] - The company plans to amend the VERSATILE-003 trial to include PFS as a primary endpoint alongside median overall survival, based on the strong data from VERSATILE-002 [8][9] Market Data and Key Metrics Changes - The company highlighted that HPV-positive head and neck cancer is becoming a significant medical issue, with over 90% of HPV-positive oropharyngeal cancers being HPV-16 positive [11][30] - Recent market research indicates a growing incidence of HPV-positive head and neck cancer, with traditional causes like tobacco and alcohol declining [30] Company Strategy and Development Direction - The company is focusing on HPV-16 positive head and neck cancer, believing it will become the dominant type of head and neck cancer in the next decade [30][31] - The company is engaging with the FDA to discuss amendments to the VERSATILE-003 trial protocol, aiming to potentially shorten the time to regulatory submission while maintaining median overall survival as an endpoint for full approval [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 as a well-tolerated treatment option for HPV-16 positive patients, who currently lack effective therapies [11][30] - The management noted that the industry is recognizing the growing problem of HPV-positive head and neck cancer, which is reflected in recent publications and market research [10][30] Other Important Information - The National Cancer Institute presented new clinical data at the 2025 Society for Immunotherapy of Cancer meeting, validating the scientific basis of the company's immunotherapy platforms [12][13] - The colorectal cancer cohort of the phase two clinical trial with PDS01ADC met criteria for expansion to stage two following positive results [13] Q&A Session Summary Question: How will the company handle patients already enrolled in the VERSATILE-003 trial during the protocol pause? - The company will continue to treat patients already enrolled in the trial and will discuss their incorporation into the trial with the FDA [20][22] Question: What is the expected PFS for the control Keytruda? - The company conservatively assumes that the PFS in the control arm will be around three months, based on previous studies [26][27] Question: How is the company addressing physician training and awareness regarding pseudoprogression in the VERSATILE-003 study? - The company has trained investigators to recognize pseudoprogression and will conduct central reviews of scans to ensure accurate assessments [39][40]

Financial Data and Key Metrics Changes - The company reported revenue of $438 million for Q3 2025, representing a 14% year-over-year increase, with year-to-date revenue of $1.27 billion also up 14% [18] - Adjusted EBITDA for Q3 was $111 million, reflecting a 16% growth year-over-year, while year-to-date adjusted EBITDA reached $330 million, up 13% [19] - Net income for Q3 was $33 million, a significant improvement from a loss of $6 million in the prior year, with adjusted net income of $48 million, up 47% year-over-year [20] Business Line Data and Key Metrics Changes - North America revenue in Q3 was $331 million, an increase of 14%, driven by robust growth across all three end markets [21] - International revenue was $107 million, a 12% increase, with growth balanced across mature and developing markets [23] - Adjusted EBITDA margin for North America was 29%, flat year-over-year, while international adjusted EBITDA margin declined modestly in Q3 compared to the prior year [22][24] Market Data and Key Metrics Changes - The company holds approximately 40% market share in North America and serves customers in 150 countries, indicating strong global presence [7][8] - The U.S. commercial laundry market is estimated to be a $6 billion market, with over 20,000 retail locations [6] - Emerging markets are seen as having significant growth potential, particularly in the vended market [14] Company Strategy and Development Direction - The company focuses on producing high-quality, reliable commercial laundry systems, emphasizing total cost of ownership (TCO) [8][12] - A clear growth strategy is in place, targeting long-term sustainable performance through innovation and market expansion [13] - The company is committed to deleveraging and maintaining a disciplined approach to capital allocation, with a focus on organic growth and selective acquisitions [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the laundry industry, highlighting its essential nature and ability to provide downside protection during economic downturns [5][6] - The company anticipates a moderation in growth rates for Q4, projecting mid-single-digit revenue growth, but remains optimistic about long-term prospects [29] - Management noted that the company is well-prepared for potential supply chain challenges, maintaining sufficient inventory and alternative sourcing options [33] Other Important Information - The company has successfully reduced its net leverage ratio to approximately 3.1 times following the IPO, enhancing financial flexibility [17][27] - Recent innovations include the launch of ScanPayWash, a cashless payment technology, and the Stax X product, designed for high throughput in limited spaces [16] Q&A Session Summary Question: How have competitors responded to the tariffs? - Management noted that one small Asian competitor increased prices by 16.5%, but overall, there has been little notable activity from competitors [31] Question: What are the strategic benefits of acquiring distributors? - The acquisition of distributors allows for closer customer relationships and targeting of high-opportunity urban markets, enhancing growth potential [32] Question: How is the company managing supply chain challenges? - Management reported no significant supply chain issues, maintaining adequate inventory levels and alternative sources of supply [33] Question: What progress has been made in expanding digital solutions? - The company is focused on long-term growth in digital solutions, with early success in the ScanPayWash technology, indicating strong potential for future revenue [34] Question: What is the outlook for the CIH segment given consumer spending headwinds? - Management indicated strong demand for their commercial-grade products, with no changes in delivery timelines [35] Question: What are the plans for further deleveraging? - The company aims to continue deleveraging through strong free cash flow and will consider returning capital to shareholders in the future [37] Question: What is the expected trajectory into Q4? - Management expects a return to a more normalized growth rate in Q4, with no changes in demand or customer sentiment [39] Question: How will pricing actions impact future profitability? - Management confirmed that pricing increases implemented throughout the year will benefit future profitability, with no history of price reductions [53]

Financial Data and Key Metrics Changes - The company reported a core EPS growth of 16% year-over-year, supported by record core earnings and strong underlying business growth across various segments [9][12][27] - The LICAT ratio remained strong at 138%, indicating a solid capital position, while the leverage ratio improved to 22.7% [9][26] - Book value per share increased by 7% year-over-year, reflecting continued capital return to shareholders [9][25] Business Line Data and Key Metrics Changes - Insurance new business performance showed growth of 15% or greater in new business CSM across all segments, with total new business CSM increasing over 20% year-over-year for the fifth consecutive quarter [8][12][13] - Asia segment reported a 29% year-on-year increase in core earnings, with APE sales up 5% and new business CSM increasing by 18% [10][19] - Global WAM experienced net outflows of $6.2 billion but maintained a record level of core earnings with a 19% increase in pre-tax core earnings [8][20][21] - The U.S. segment saw APE sales growth of 51%, but core earnings decreased by 20% due to unfavorable life insurance claims experience [24][25] Market Data and Key Metrics Changes - The company is expanding into the Indian insurance market through a joint venture with Mahindra, aiming to leverage local expertise and distribution [6][30] - The company continues to focus on Asia and global WAM for growth opportunities, with a strong emphasis on digital innovation and AI [7][10] Company Strategy and Development Direction - The refreshed enterprise strategy aims to build on strengths and focus on sustainable growth, with a diversified portfolio to mitigate risks [5][6][8] - The company plans to enhance its leadership position in its home market while maintaining a scaled presence in the U.S. [6][7] - Investments will be made to leverage AI capabilities and improve customer engagement [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2027 financial targets, emphasizing the importance of diversified growth across segments [9][27] - The company remains optimistic about the fundamentals in Asia, particularly in markets like China and Singapore [32][33] - Management acknowledged challenges in net flows but highlighted strong core earnings generation and operational resilience [12][27] Other Important Information - The company returned nearly $4 billion of capital to shareholders year-to-date through dividends and share buybacks [25][26] - The annual actuarial review resulted in a favorable impact on reserves, validating the prudence of the company's reserves [18][48] Q&A Session Summary Question: Details on the India venture - Management highlighted the favorable regulatory environment and digital infrastructure in India, with expectations to launch operations within 12-18 months [30][31] Question: Outlook for Asia markets - Continued strong sales growth is expected in Asia, with broad-based success across multiple markets [32][33] Question: Private credit exposure - The company has a CAD 4 billion below-investment-grade private credit portfolio, focusing on middle-market lending [34] Question: Impact of mandatory provident fund fee changes - Guidance remains intact for a $25 million quarterly impact post-transition, with expectations for improved margins [36][37] Question: Actuarial review impact - The annual review led to a reserve reduction of $605 million, positively impacting core earnings [48][49] Question: U.S. business strategy - The focus remains on high net worth customers, with no intention to revert to previous high-risk products [57][58]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved organic net sales growth of 2.5%, aligning with expectations despite external pressures [7][22] - Adjusted gross margin rate decreased by 330 basis points, primarily due to unexpected year-end inventory adjustments and increased trade promotions [26][28] - Adjusted operating income was $40.3 million, representing 7.5% of net sales, down from 10.8% the previous year [28] Business Line Data and Key Metrics Changes - International organic net sales grew by 6.9%, driven by volume and price gains across all segments [22] - North America experienced a decline in organic net sales by 60 basis points, with wet shave sales declining approximately 1% [23] - Sun and skin care organic net sales increased by approximately 11%, with robust growth across each business segment [24] Market Data and Key Metrics Changes - International markets, representing about 40% of global sales, delivered strong growth for the fourth consecutive year, with Europe achieving its third straight year of growth [8][9] - The U.S. razor and blades category saw consumption down by 80 basis points, although market share improved sequentially [23] - The Billie brand achieved a 90 basis point share growth, indicating strong retail performance [24] Company Strategy and Development Direction - The company plans to divest its feminine care business to focus on core categories with competitive advantages, including shave, sun, and skincare [6][20] - A multi-year innovation roadmap is being implemented, with significant investments in brand building and marketing to restore brand equity [11][14] - The transformation plan aims to simplify the U.S. structure, enhance decision-making speed, and increase investment in growth capabilities [12][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging fiscal 2025 due to external pressures like tariffs and geopolitical tensions, but expressed optimism about durable international growth and innovation [8][20] - The outlook for fiscal 2026 anticipates a return to organic net sales growth, driven by mid-single-digit growth in international markets and stabilization in North America [16][34] - The company expects to face continued inflation and tariff impacts but is focused on productivity gains and margin recovery [16][36] Other Important Information - The company declared a quarterly dividend of $0.15 per share for Q4 and completed approximately $90 million in share repurchases for the fiscal year [29] - The anticipated divestiture of the feminine care business is expected to impact adjusted EPS by approximately $0.40-$0.50 annually [32] Q&A Session Summary Question: Outlook and EPS Expectations - The company expects a balanced and achievable plan for 2026, with EPS potentially at a loss in Q1 due to margin pressures and tax rate changes [40][41] Question: Strategy and Portfolio Focus - The strategy focuses on winning in shave, grooming, sun, and skin categories, with plans for potential M&A as asset values decline [45][46] Question: Productivity and Gross Margin Concerns - Management expressed confidence in the second-half-oriented plan, expecting higher sales growth and productivity improvements to enhance gross margin [50][52] Question: Use of Proceeds from Divestiture - Proceeds from the feminine care sale will primarily be used for debt reduction, with a focus on maintaining a disciplined capital allocation strategy [54][55] Question: Sun and Skin Category Outlook - The company plans conservatively for the sun category, expecting low single-digit growth while investing in brand campaigns for Hawaiian Tropic and Banana Boat [57][58]

Financial Data and Key Metrics Changes - Overall third quarter revenue was $295.3 million, down 9.8% sequentially and 12.2% year-over-year [16] - Adjusted EBITDA for Q3 2025 was $64 million, representing a margin of 21.7%, consistent with Q2 2025 levels despite lower revenues [17] - Adjusted EPS for Q3 2025 was $0.16, including adjustments totaling $2.3 million [18] - Gross debt totaled $332.9 million, and net debt was $263.3 million, with a net debt-to-adjusted EBITDA ratio of 0.93 [19] Business Line Data and Key Metrics Changes - Revenue decline was primarily due to the transition between major contracts in Saudi Arabia, partially offset by growth in Kuwait, Qatar, and Iraq [16][17] - Growth was noted in Kuwait, Oman, Egypt, Algeria, Iraq, and Libya, indicating a diversified performance across regions [17] Market Data and Key Metrics Changes - The company is experiencing a positive activity inflection in Kuwait and Saudi Arabia, with increased activities across most operational countries [5][6] - The Gulf Cooperation Council (GCC) is positioned as a leader in the AI revolution, which is expected to drive energy demand [6][7] Company Strategy and Development Direction - The company has secured a multi-billion dollar contract for the Jafurah project, which is a cornerstone achievement and part of a broader growth strategy [4][10] - NESR's countercyclical investment strategy allows it to capitalize on global market weaknesses, positioning the company for growth while others are cutting back [12][13] - The company aims to maintain operational readiness and efficiency while investing during downturns, which is expected to yield long-term benefits [14][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $2 billion revenue run rate by the end of 2026, supported by awarded contracts and operational execution [20][72] - The outlook for 2026 and beyond remains positive, with expectations of continued growth driven by strategic investments and market opportunities [24][73] Other Important Information - The company is in the process of refinancing its debt facility, expected to enhance financial flexibility [23] - NESR is focused on maintaining disciplined debt reduction and improving working capital efficiency [24] Q&A Session Summary Question: Can you explain how NESR was able to price competitively for the Jafurah contract while maintaining margins? - Management highlighted their deep understanding of the local ecosystem and cost control measures that allowed them to maintain profitability [30][31] Question: What is the roadmap for development at Jafurah and expected activity levels? - Management indicated plans to ramp up to 1,500 stages per month by 2026, with flexibility to adjust based on client needs [34][35] Question: What is the expected incremental EBITDA from the Jafurah project? - Management confirmed an approximate incremental EBITDA of $100 million for 2026, based on current margins [38] Question: Can you provide updates on NEDA projects and water initiatives? - Management stated that several pilot projects are underway, with results expected to be shared in future calls [66][68] Question: What is the confidence level in achieving the $2 billion exit run rate for 2026? - Management expressed a 99% confidence level in achieving the $2 billion run rate, supported by signed contracts and ongoing work [72]